What is Monopar Therapeutics's market cap?

Monopar Therapeutics (MNPR) has a market capitalization of $779.4M and trades on NASDAQ.

Who are Monopar Therapeutics's competitors?

Monopar Therapeutics's key competitors include Bristol Myers Squibb, Eli Lilly and Company, Ultragenyx Pharmaceutical Inc., and others. These companies compete in similar markets and product categories.

Who does Monopar Therapeutics partner with?

Monopar Therapeutics's notable partners include Alexion, AstraZeneca Rare Disease, NorthStar Medical Radioisotopes, LLC, XOMA Ltd., and others.

Where is Monopar Therapeutics headquartered?

Monopar Therapeutics is headquartered in United States of America and employs approximately 12 people. It has been publicly traded since 2019.

Monopar Therapeutics (MNPR) Stock Fundamentals & Financials

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics for rare diseases and advanced cancers.

Market cap

$779.44M+280%

Net income-$15.0M+9.6%

Trailing twelve months · change vs. prior year

Earnings

Q1 2026 report

May 14, 2026

Revenue-EPS-$0.46Beat by $0.60

Read the full report

Next report

Nov 6, 2026 (in 3 months)

EPS estimate-$0.77

Financials

Q1 2026

Income statement

See full

Revenue-—

Operating income-$5.2M-62.2%

Net income-$3.9M-48.3%

Balance sheet

See full

Cash & equivalents$52.5M+32.3%

Total debt$230.4K+2,692%

Total equity$135.4M+153%

Total assets$138.0M+150%

Cash flow

See full

Operating cash flow-$3.5M+38.7%

Valuation & ratios

Valuation

See full

Market cap$798.6M+280%

Enterprise value$746.28M+378%

Returns & leverage

See full

Return on equity-15.9%-6.6pp

Debt / equity0×0.0×

Current ratio56×—

Competitors

By market cap

Eli Lilly$1.06T+88.4%

Bristol-Myers Squibb$132.20B+41.4%

Ultragenyx Pharmaceutical$2.6B-3.8%

Bausch Health Companies$2.3B+9.9%

Wave Life Sciences$1.2B-6.6%

Monopar Therapeutics$798.6M+277%

Prime Medicine$558.6M-17.2%

Atrium Therapeutics$211.1M-96.2%

By revenue growth

Eli Lilly+49.6%

Ultragenyx Pharmaceutical+17.5%

Bausch Health Companies+8.2%

Bristol-Myers Squibb+3.1%

Wave Life Sciences-47.2%

By net margin

Eli Lilly33.53%+7.6pp

Bristol-Myers Squibb18.87%+8.4pp

Bausch Health Companies-1.88%-9.1pp

Wave Life Sciences-66.5%-173pp

Ultragenyx Pharmaceutical-81.7%+5.6pp

Prime Medicine-4,342.44%—

Profile

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics for rare diseases and advanced cancers. The company's core value proposition lies in its dual-track pipeline featuring a late-stage treatment for Wilson disease and a novel radiopharmaceutical platform targeting the urokinase plasminogen activator receptor (uPAR).

Competitive position

Monopar is a clinical-stage developer leveraging licensed late-stage assets and proprietary antibody platforms to compete in the high-growth radiopharmaceutical and orphan drug markets.

GeographiesUnited States, Australia, European Union

Customer segmentsRare disease patients, Cancer patients, Healthcare providers

Business modelDrug development, IP Licensing

SuppliersContract Manufacturing Organizations (CMOs), Radioisotope suppliers, Clinical Research Organizations (CROs), Academic research institutions

CustomersSpecialty pharmacies, Hospitals, Cancer treatment centers, Nuclear oncology clinics

CountryUnited States of America

Listed2019

Employees12.0

CEOChandler D. Robinson

SectorHealthcare

IndustryBiotechnology

Websitemonopartx.com

FilingsSEC EDGAR

FAQ

What is Monopar Therapeutics's market cap?: Monopar Therapeutics (MNPR) has a market capitalization of $779.4M and trades on NASDAQ.
Who are Monopar Therapeutics's competitors?: Monopar Therapeutics's key competitors include Bristol Myers Squibb, Eli Lilly and Company, Ultragenyx Pharmaceutical Inc., and others. These companies compete in similar markets and product categories.
Who does Monopar Therapeutics partner with?: Monopar Therapeutics's notable partners include Alexion, AstraZeneca Rare Disease, NorthStar Medical Radioisotopes, LLC, XOMA Ltd., and others.
Where is Monopar Therapeutics headquartered?: Monopar Therapeutics is headquartered in United States of America and employs approximately 12 people. It has been publicly traded since 2019.